Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NYSEARCA:DBV NASDAQ:GRI NYSE:RTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$169.90-4.1%$169.61$111.09▼$183.00$10.83B0.38506,841 shs617,646 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AGRIGRI Bio$1.82-6.7%$1.44$1.10▼$43.69$4.87M-1.62158,905 shs242,429 shsRTIRTI International Metals$0.00$0.00▼$0.00N/AN/AN/AN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-4.12%-2.89%-0.47%+2.94%+22.61%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%GRIGRI Bio-6.67%+9.64%+30.00%+20.53%-93.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.6293 of 5 stars4.53.00.00.02.91.70.6DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AN/AN/AGRIGRI Bio3.0524 of 5 stars3.54.00.00.03.00.01.3RTIRTI International MetalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$223.0731.29% UpsideDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AGRIGRI Bio 3.00Buy$22.001,108.79% UpsideRTIRTI International Metals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RTI, ASND, DBV, and GRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$213.00 ➝ $243.007/3/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$250.006/13/2025ASNDAscendis Pharma A/SOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.006/11/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/9/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$201.00 ➝ $216.006/3/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$196.00 ➝ $201.005/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.005/12/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.005/5/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.005/2/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.005/2/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M26.39N/AN/A($1.88) per share-90.37DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/A$7.68 per shareN/ARTIRTI International MetalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$6.28N/A707.92N/A-93.22%N/A-33.29%9/2/2025 (Estimated)DBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/AGRIGRI Bio-$8.21M-$11.56N/AN/AN/AN/A-275.15%-168.22%8/12/2025 (Estimated)RTIRTI International MetalsN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest RTI, ASND, DBV, and GRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GRIGRI Bio-$1.31N/AN/AN/AN/AN/A5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/A5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ADBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/ARTIRTI International MetalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.040.71DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AGRIGRI BioN/A1.411.41RTIRTI International MetalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ADBVInvesco DB G10 Currency Harvest Fund85.24%GRIGRI Bio33.95%RTIRTI International MetalsN/AInsider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%DBVInvesco DB G10 Currency Harvest FundN/AGRIGRI Bio0.13%RTIRTI International MetalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableGRIGRI Bio12.50 million2.49 millionNot OptionableRTIRTI International MetalsN/AN/AN/ANot OptionableRTI, ASND, DBV, and GRI HeadlinesRecent News About These CompaniesRTI International CEO on drastic funding cuts and his NC nonprofit’s market pivotJune 27, 2025 | msn.comLightstorm finishes integrating subsea cables bought from RTIMay 9, 2025 | datacenterdynamics.comDRTI INTERNATIONAL METALS (NYSE: RTI) - Share Price and ResearchMay 6, 2025 | intelligentinvestor.com.auIRTI International layoffs expected to reach at least 525 by May 1, organization saysMarch 27, 2025 | wral.comWRTI International layoff expected to reach at least 525 by May 1, organization saysMarch 27, 2025 | msn.comOpen Source: RTI International CEO makes seven figures. Does that justify USAID cuts?February 21, 2025 | msn.comRTI International to temporarily lay off staff due to US foreign aid freezeFebruary 14, 2025 | wunc.orgWRTI International lays off US workers, including in NC, citing Trump’s USAID cutsFebruary 13, 2025 | msn.comRTI International layoffs hit NC due to US freeze on foreign aidFebruary 13, 2025 | wral.comWResearch Urges Tyre Particles as Unique Eco ThreatNovember 14, 2024 | miragenews.comMA digital exam reels in engraved scenes of Stone Age net fishingNovember 7, 2024 | sciencenews.orgSRussia explores creation of international precious metals exchangeOctober 26, 2024 | msn.comRussia in talks with BRICS over precious metals exchangeOctober 24, 2024 | reuters.comRTI Joins the Common Vulnerabilities and Exposures (CVE®) Program as a CVE Numbering Authority (CNA)October 22, 2024 | markets.businessinsider.comRTI Awarded Elite Supplier Status by Lockheed Martin's Rotary and Mission Systems (RMS) DivisionOctober 15, 2024 | tmcnet.comAnalysts Conflicted on These Materials Names: Coeur Mining (CDE), RPM International (RPM) and Rio Tinto Limited (OtherRTNTF)October 10, 2024 | markets.businessinsider.comEnergy transition story rekindles fund interest in metalsOctober 7, 2024 | reuters.comJai Bhim Nagar Demolition: Mumbai Police To File FIR Against BMC Officers And PolicemenOctober 4, 2024 | msn.comRTI International Teams Up with USAID, UNICEF to Create a Lead-Free FutureOctober 4, 2024 | morningstar.comMMumbai: BMC Reveals Construction Of Two-Level Underground Parking Lot At Breach Candy In Response To RTI Amid Resident ConcernsOctober 3, 2024 | freepressjournal.inFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseWhat to Expect From the Q2 Earnings Reporting CycleBy Thomas Hughes | June 23, 2025View What to Expect From the Q2 Earnings Reporting CycleThe Meteoric Rise of Rocket Lab: A Space Stock to WatchBy Ryan Hasson | July 11, 2025View The Meteoric Rise of Rocket Lab: A Space Stock to Watch3 Hot Tech Stocks Showing Bullish Price Action Right NowBy Thomas Hughes | July 11, 2025View 3 Hot Tech Stocks Showing Bullish Price Action Right NowRTI, ASND, DBV, and GRI Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$169.90 -7.30 (-4.12%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$171.00 +1.10 (+0.65%) As of 07/18/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Invesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.GRI Bio NASDAQ:GRI$1.82 -0.13 (-6.67%) As of 07/18/2025 03:59 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.RTI International Metals NYSE:RTIRTI International Metals, Inc. is a producer and global supplier of titanium mill products and a manufacturer of fabricated titanium and specialty metal components for the national and international aerospace, defense, energy, medical device, and other consumer and industrial markets. The Company operates in two segments: the Titanium segment and Engineered Products and Services (EP&S) segment. The Titanium Segment melts, processes, produces, forges, stocks, distributes, finishes, cuts-to-size, and facilitates just-in-time delivery services of a complete range of titanium mill products, which are further processed by its customers for use in a variety of commercial aerospace, defense, and industrial and consumer applications. The EP&S Segment is comprised of companies with significant hard and soft-metal expertise that form, extrude, fabricate, machine, additively manufacture, micro-machine, and assemble titanium, aluminum, and other specialty metal parts and components. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
